Glycomine raises $12M in series A round

Rare disease company Glycomine Inc. (San Francisco, Calif.) raised $12 million in a series A round led by Sanderling Ventures and Chiesi Ventures.

The company's preclinical lead program is substrate replacement therapy Lipo-M1P to treat congenital disorder of glycosylation Type Ia (CDG-Ia). The therapy uses Glycomine’s liposomal delivery technology to release the mannose-1-phosphate substrate within the cell. President and CEO Agnes Rafalko told BioCentury that Glycomine hopes to begin a clinical trial of Lipo-M1P in 2018...